One-Liner
A per-drug onboarding pack produced within 48 hours of each new FDA specialty drug approval, sold to hospital inpatient pharmacy directors at $99-199 per pack covering distributor contacts, patient assistance pathways, cold-chain handling, and formulary procedures.
AI Thinking Process
Hospital pharmacist at 200-bed community hospital gets first prescription for newly-approved niche antiviral Hepcludex; must figure out formulary status, specialty pharmacy routing, patient assistance, cold-chain — currently loses 4-8 hours per new drug in cold calls
First instinct was 'this is an Epic feature' — rejected via G167 artifact-owner check: Epic owns formulary record but NOT the specialty pharmacy distribution playbook or patient assistance pathway for a brand-new drug. G167 passes.
Checked GoodRx, CoverMyMeds, RxBenefits — all handle outpatient PBM friction, not hospital inpatient first-dispense. Prior session idea (20260516 Specialty Pharmacy Onboarding Platform) targets regional specialty pharmacies, not hospital inpatient pharmacy directors. Different segment.
Verb Transplant: 'vendor onboarding pack' from procurement/IT departments. Product becomes per-pack micro-subscription ($199/new drug) sold to pharmacy directors rather than a seat-based SaaS.
WHO: Hospital inpatient pharmacy director at 100-500 bed community hospital (~3,500 US hospitals). CURRENT: 4-8 hours cold calls per new specialty drug. WHY-SURPRISED: FDA approving 50-70 specialty drugs/year with no 48-hour post-approval onboarding pack product.
Frequency Trap check (G008): 5-15 new specialty drugs/year per 200-bed hospital at $199/pack = $1,000-3,000/year per hospital. 3,500 hospitals × $2,000 average = $7M TAM. Not venture-scale.
Survived at 42% conviction — below painpoint threshold but held for Pass 2 stress-test. Biggest worry: TAM ceiling.
Two of four structural claims are single-source: FDA approval rate claim (unverified for 2026 specifically) and pharmacist 4-8 hour time loss (no surveyed source). Conviction capped at 45%.
First 10 customers: ASHP regional chapter dinners + ASHP Midyear Clinical Meeting booth. 6-12 week committee approval per hospital. Solo founder can close 30-50/year. $1M ARR takes 3-4 years.
TAM ceiling ($7M absolute) combined with conviction cap at 45% from unverified signals places this below painpoint flavor 50% threshold. TAM too small for venture, sales cycle too long for solo founder. KILLED IN DEEPENING.
Kill Reason
TAM ceiling of approximately $7M absolute (3,500 US community hospitals × $2,000 average spend), conviction capped at 45% by two unverified single-source claims on FDA approval rates and pharmacist time loss, and 6-12 week sales cycles per hospital — creating a 3-4 year path to $1M ARR even with perfect execution.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Structural subset of T1's per-pack onboarding kit — the video library is a thinner product that the onboarding pack already includes. Forking the same thread produces a weaker version of a product already identified as having a TAM ceiling problem.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.